1. CELG needs the disputed CYCC patent rights to develope its five other drugs.
2. CYCC's sapacitabine likely to be the ideal treatment for AML, MDS and solid tumors, which will directly compete with CELG's major pipelines.
3. CYCC's present tiny market cap would be a cheap buy.
Therefore, CYCC has become the prefect target for CELG to acquire.